DnB Asset Management AS Sells 475 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

DnB Asset Management AS lessened its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 7.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,778 shares of the company’s stock after selling 475 shares during the quarter. DnB Asset Management AS’s holdings in Janux Therapeutics were worth $309,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JANX. Intech Investment Management LLC bought a new position in shares of Janux Therapeutics in the third quarter worth about $368,000. Charles Schwab Investment Management Inc. increased its position in Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after buying an additional 156,675 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Janux Therapeutics by 27.2% during the third quarter. The Manufacturers Life Insurance Company now owns 30,595 shares of the company’s stock worth $1,390,000 after buying an additional 6,547 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Janux Therapeutics by 40.0% in the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after acquiring an additional 721,563 shares during the period. Finally, Polar Asset Management Partners Inc. acquired a new stake in shares of Janux Therapeutics in the third quarter worth $613,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on JANX. Scotiabank reduced their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 28th. Wedbush restated an “outperform” rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Janux Therapeutics has a consensus rating of “Buy” and a consensus target price of $92.44.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO David Alan Campbell sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 293,054 shares of the company’s stock, valued at $17,583,240. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,668 shares of company stock worth $548,183. 29.40% of the stock is currently owned by insiders.

Janux Therapeutics Stock Up 5.4 %

Shares of Janux Therapeutics stock opened at $28.25 on Thursday. Janux Therapeutics, Inc. has a 12-month low of $26.03 and a 12-month high of $71.71. The stock has a market capitalization of $1.67 billion, a P/E ratio of -24.15 and a beta of 3.23. The company has a 50-day simple moving average of $34.81 and a 200 day simple moving average of $45.59.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.